Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.50 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553830 | 0.88 | L3MBTL1 (0.62) | L3MBTL1KLKB1POLBTDP1HSD17B10 | |
| SCHEMBL13692389 | 0.85 | L3MBTL1 (0.54) | L3MBTL1KLKB1POLBTDP1HSD17B10 | |
| SCHEMBL15964732 | 0.85 | KLKB1 (0.60) | L3MBTL1KLKB1POLBTDP1HSD17B10 | |
| SCHEMBL949612 | 0.84 | KLKB1 (0.53) | KLKB1POLBHSD17B10KDM4EALDH1A1 | |
| SCHEMBL949478 | 0.83 | HDAC6 (0.46) | L3MBTL1KLKB1POLBTDP1CREBBP | |
| SCHEMBL15309597 | 0.83 | L3MBTL1 (0.51) | L3MBTL1KLKB1POLBTDP1HSD17B10 | |
| SCHEMBL15143107 | 0.83 | L3MBTL1 (0.55) | L3MBTL1KLKB1POLBTDP1HSD17B10 | |
| SCHEMBL20250854 | 0.83 | CREBBP (0.54) | L3MBTL1KLKB1POLBTDP1HSD17B10 | |
| SCHEMBL3765456 | 0.81 | KLKB1 (0.53) | L3MBTL1KLKB1POLBTDP1HSD17B10 | |
| SCHEMBL6426563 | 0.81 | KLKB1 (0.53) | L3MBTL1KLKB1POLBTDP1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762377-B1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | UNIV CORNELL (US) | 2025-08-20 | — | — | EP | disclosed |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | CORNELL UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3762377-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | Cook, Timothy, H. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2020-12-31 | — | — | US | disclosed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| WO-2019173790-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | HLA TIMOTHY (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2018-08-30 | — | — | US | disclosed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | disclosed |
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8916591-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2014-12-23 | — | — | US | disclosed |
| EP-2294065-B1 | INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS R&D LTD (GB) | 2014-03-19 | — | — | EP | disclosed |
| CN-101970424-B | Indolylpyridone derivatives with checkpoint kinase 1 inhibitory activity | VERNALIS R&D LTD | 2013-06-12 | — | — | CN | disclosed |
| CN-101970424-A | Indolylpyridone derivatives with checkpoint kinase 1 inhibitory activity | VERNALIS R&D LTD | 2011-02-09 | — | — | CN | disclosed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | L3MBTL1 806/4885KLKB1 2234/4885POLB 826/4885 |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | L3MBTL1 1632/4885KLKB1 884/4885POLB 1630/4885 |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | L3MBTL1 806/4885KLKB1 2234/4885POLB 826/4885 |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | L3MBTL1 1632/4885KLKB1 884/4885POLB 1630/4885 |
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | PTGER1, LOXL1, COL1A1 | L3MBTL1 1788/4885KLKB1 2322/4885POLB 3175/4885 |
| US-20180244652-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK2, CHEK1, BUB1B | L3MBTL1 1632/4885KLKB1 884/4885POLB 1630/4885 |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | CHEK1, CHEK2, BUB1 | L3MBTL1 1181/4885KLKB1 1071/4885POLB 1128/4885 |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | PTGER1, LOXL1, COL1A1 | L3MBTL1 1788/4885KLKB1 2322/4885POLB 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.